Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaptesed pegol - TME Pharma

Next Previous
Drug Profile

Olaptesed pegol - TME Pharma

Alternative Names: Anti-CXCL12/SDF-1 Spiegelmer®; NOX-A12

Latest Information Update: 16 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NOXXON Pharma AG
  • Developer TME Pharma
  • Class Antineoplastics; Eye disorder therapies; Oligonucleotides; Polyethylene glycols; Small molecules
  • Mechanism of Action Chemokine CXCL12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Multiple myeloma
  • Phase I/II Colorectal cancer; Glioblastoma; Pancreatic cancer
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data form phase-I/II GLORIA trial for Glioblastoma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 28 Jun 2023 Updated efficacy data from the phase I/II GLORIA trial in Glioblastoma released by TME Pharma
  • 15 Jun 2023 US FDA approves the phase II OPTIMUS trial protocol for Olaptesed pegol in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top